Strides Pharma

What does Strides Pharma do?

Strides Pharma Science Ltd is a mid-cap pharmaceutical company that specializes in the development and manufacturing of generic and specialty medicines. As of March 2025, it reported net sales of ₹1,190 Cr and a net profit of ₹82 Cr.

Overview:<BR>Strides Pharma Science Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>The company was originally incorporated as 'Strides Arcolab Limited' in 1990. It underwent a merger with Shasun Pharmaceuticals Limited in FY 2016, resulting in the formation of 'Strides Shasun Limited' on November 19, 2015. The name was changed to 'Strides Pharma Science Limited' on July 18, 2018. The latest reported quarter for sales and profit is March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,190 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 82 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 7,241 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.32%<BR>- Debt Equity: 0.66<BR>- Return on Equity: 13.42%<BR>- Price to Book: 2.84<BR><BR>Contact Details:<BR>Address: No 201 Devavrata Sector 17, Vashi Navi Mumbai Maharashtra : 400703<BR>Tel: 91-22-27892924/27893199<BR>Email: investors@stridesshasun.com<BR>Website: http://www.stridesarco.com

Has Strides Pharma declared dividend?

Strides Pharma Science Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of September 9, 2024. Despite low dividend yields, the company has shown strong price appreciation, with total returns of 86.82% over the past year and 355.21% over the last two years.

Strides Pharma Science Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: Sep-09-2024<BR><BR>Dividend Yield: 0.32%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 10.3%, with a dividend return of 0%, resulting in a total return of 10.3%.<BR><BR>Over the past year, the price return was 86.26%, the dividend return was 0.56%, leading to a total return of 86.82%.<BR><BR>In the 2-year period, the price return stood at 353.24%, with a dividend return of 1.97%, culminating in a total return of 355.21%.<BR><BR>For the 3-year period, the price return was 402.18%, the dividend return was 2.81%, resulting in a total return of 404.99%.<BR><BR>In the last 4 years, the price return was 108.0%, with a dividend return of 1.75%, giving a total return of 109.75%.<BR><BR>Over the past 5 years, the price return reached 292.97%, while the dividend return was 4.29%, leading to a total return of 297.26%.<BR><BR>Overall, Strides Pharma has declared a dividend, and the total returns over various periods indicate strong price appreciation, particularly in the longer term, despite relatively low dividend returns.

Who are the peers of the Strides Pharma?

Strides Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, FDC, SPARC, Supriya Lifesciences, and Innova Captab. Strides Pharma has below average management and capital structure risks, with a 1-year return of 92.02%, outperforming peers like Torrent Pharma, which has the lowest return at 1.55%.

Peers: The peers of Strides Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, FDC, SPARC, Supriya Lifesci., and Innova Captab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Supriya Lifesci., while Good management risk is found at Divi's Lab., Torrent Pharma, and Innova Captab. Below Average management risk is noted for Strides Pharma, SPARC, and Sequent Scien. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Divi's Lab., Torrent Pharma, Strides Pharma, SPARC, and FDC. Excellent capital structure is present in Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and FDC, while Good capital structure is noted for Torrent Pharma, and Below Average capital structure is found at Strides Pharma, SPARC, and Sequent Scien.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Torrent Pharma at 1.55%. Strides Pharma's 1-year return of 92.02% is significantly higher than both. Additionally, FDC, SPARC, and Torrent Pharma have negative six-month returns.

Who are in the management team of Strides Pharma?

As of March 2023, the management team of Strides Pharma includes Arun Kumar (Chairperson & Managing Director), S Sridhar, Bharat D Shah, Homi Rustam Khusrokhan (all Non-Executive & Independent Directors), Manjula Ramamurthy (Company Secretary), Badree Komandur (Executive Director, Finance), and Kausalya Santhanam (Non-Executive & Independent Director). This team oversees the company's operations and strategic direction.

As of March 2023, the management team of Strides Pharma includes the following individuals:<BR><BR>1. Arun Kumar - Chairperson & Managing Director<BR>2. S Sridhar - Non-Executive & Independent Director<BR>3. Bharat D Shah - Non-Executive & Independent Director<BR>4. Manjula Ramamurthy - Company Secretary & Compliance Officer<BR>5. Homi Rustam Khusrokhan - Non-Executive & Independent Director<BR>6. Badree Komandur - Executive Director (Finance)<BR>7. Kausalya Santhanam - Non-Executive & Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the top shareholders of the Strides Pharma?

The top shareholders of Strides Pharma include Pronomz Ventures LLP with 19.58%, foreign institutional investors holding 28.32%, and mutual funds at 8.89%. Individual investors own 21.51% of the shares, with Quant Mutual Fund being the largest public shareholder at 5.4%.

The top shareholders of Strides Pharma include a mix of institutional and individual investors. The largest promoter holding is Pronomz Ventures LLP, which holds 19.58%. The company has a significant portion of its shares pledged by promoters, amounting to 51.9788%. <BR><BR>In terms of institutional investors, mutual funds hold about 8.89% of the shares through 11 different schemes, while foreign institutional investors (FIIs) account for 28.32% of the holdings, represented by 228 FIIs. The highest public shareholder is Quant Mutual Fund, specifically the Quant Business Cycle Fund, which holds 5.4%. Additionally, individual investors collectively hold 21.51% of the shares.

How big is Strides Pharma?

As of 24th July, Strides Pharma Science Ltd has a market capitalization of 8,521.00 Cr, with recent net sales of 4,598.50 Cr and a net profit of 312.18 Cr.

As of 24th July, Strides Pharma Science Ltd has a market capitalization of 8,521.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Strides Pharma reported Net Sales of 4,598.50 Cr and a Net Profit of 312.18 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,551.83 Cr and Total Assets of 5,779.59 Cr.

How has been the historical performance of Strides Pharma?

Strides Pharma has shown significant recovery and growth, with net sales increasing from 2,178.37 crore in March 2019 to 4,565.34 crore in March 2025, and profit after tax rebounding to 407.57 crore in March 2025 from a loss of 89.94 crore the previous year. The company's operating profit also improved to 802.82 crore in March 2025, indicating strong financial performance.

Answer:<BR>The historical performance of Strides Pharma shows a significant recovery and growth trajectory in recent years, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Strides Pharma's net sales have shown a consistent upward trend, increasing from 2,178.37 crore in March 2019 to 4,565.34 crore in March 2025. Total operating income followed a similar pattern, reaching 4,565.34 crore in March 2025, up from 3,890.13 crore in March 2024. The company's total expenditure also rose, amounting to 3,762.52 crore in March 2025, which is higher than the previous year's 3,307.75 crore. Operating profit (PBDIT) excluding other income improved significantly to 802.82 crore in March 2025, compared to 582.38 crore in March 2024, indicating a recovery from a loss of 20.11 crore in March 2022. Profit before tax turned positive at 485.08 crore in March 2025, a notable improvement from a loss of 60.83 crore in March 2024. The profit after tax also rebounded to 407.57 crore in March 2025, compared to a loss of 89.94 crore in the previous year. The company's total assets increased to 5,779.59 crore in March 2025 from 5,572.41 crore in March 2024, while total liabilities slightly increased to 5,779.59 crore from 5,572.41 crore. Cash flow from operating activities remained positive at 684.00 crore in March 2025, although net cash outflow was recorded at -48.00 crore. Overall, Strides Pharma's financial performance reflects a strong recovery and growth in key areas, particularly in sales and profitability.

Is Strides Pharma overvalued or undervalued?

As of November 3, 2025, Strides Pharma is considered very attractive and undervalued, with a PE ratio of 20.76 and a PEG ratio of 0.00, significantly outperforming competitors like Sun Pharma and Cipla, and achieving a year-to-date return of 49.33% compared to the Sensex's 7.47%.

As of 3 November 2025, the valuation grade for Strides Pharma has moved from attractive to very attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, particularly when examining its key financial ratios. Strides Pharma has a PE ratio of 20.76, a price to book value of 0.33, and an EV to EBITDA of 23.05, which suggest that it is trading at a significant discount compared to its peers.<BR><BR>In comparison to notable competitors, Sun Pharma has a PE ratio of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a PE of 22.44 and an EV to EBITDA of 5.66. This highlights that Strides Pharma is positioned favorably within the industry, especially with its PEG ratio at 0.00, suggesting strong growth potential relative to its price. Additionally, Strides Pharma has outperformed the Sensex in various timeframes, including a year-to-date return of 49.33% compared to the Sensex's 7.47%, reinforcing the notion of its undervaluation.

Is Strides Pharma technically bullish or bearish?

As of November 27, 2025, Strides Pharma's technical trend is mildly bullish, supported by bullish weekly and monthly MACD and moving averages, despite some mixed signals from other indicators.

As of 27 November 2025, the technical trend for Strides Pharma has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. The daily moving averages are bullish, supporting the mildly bullish stance. However, the KST and OBV on a weekly basis are mildly bearish, which introduces some caution. Dow Theory shows a mildly bearish signal on the weekly chart but is bullish on the monthly chart. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from other indicators.

When is the next results date for Strides Pharma Science Ltd?

The next results date for Strides Pharma Science Ltd is January 30, 2026.

The next results date for Strides Pharma Science Ltd is scheduled for January 30, 2026.

Are Strides Pharma Science Ltd latest results good or bad?

Strides Pharma Science Ltd's latest results show a significant quarterly profit increase of 129.80% and improved operating margins, but concerns arise from reliance on exceptional income and a 22.46% decline in nine-month profits, indicating potential risks for future performance.

Strides Pharma Science Ltd's latest results present a mixed picture. On one hand, the company reported a substantial year-on-year increase in net profit for Q3 FY26, which rose by 129.80% to ₹202.11 crore. Additionally, revenue grew modestly by 3.55% to ₹1,194.65 crore, and the operating margin reached a seven-quarter high of 19.75%, reflecting improved operational efficiency.<BR><BR>However, there are significant concerns regarding the sustainability of these earnings. A large portion of the profit was driven by exceptional other income, which accounted for nearly 43% of profit before tax. This raises questions about the quality of earnings and whether such levels of other income can be expected in future quarters.<BR><BR>Moreover, when looking at the nine-month performance for FY26, the consolidated net profit declined by 22.46% compared to the same period last year, indicating underlying challenges. The company's reliance on non-operating income and the volatility in earnings trajectory suggest that while the quarterly results may look strong, the overall financial health and future outlook warrant caution.<BR><BR>In summary, while the latest quarterly results show impressive profit growth and margin expansion, the heavy reliance on exceptional income and the decline in nine-month profits highlight potential risks that could impact the company's performance moving forward.

Should I buy, sell or hold Strides Pharma Science Ltd?

Which are the latest news on Strides Pharma?

Why is Strides Pharma Science Ltd falling/rising?

As of 03-Feb, Strides Pharma Science Ltd's stock price is rising to 873.00, driven by a significant net profit growth of 133.64% and a trend reversal after previous declines. The stock has outperformed the sector and is trading at a discount compared to peers, despite some negative indicators.

As of 03-Feb, Strides Pharma Science Ltd's stock price is rising, currently at 873.00, reflecting an increase of 37.4 (4.48%). This upward movement can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after two consecutive days of decline. Additionally, it opened with a gain of 2.35% today and reached an intraday high of Rs 885.3, which is a 5.95% increase.<BR><BR>The company recently reported a significant growth in net profit of 133.64%, marking very positive results for the quarter ending December 25. This performance is part of a consistent trend, as the company has declared positive results for the last ten consecutive quarters. Furthermore, the stock has outperformed the sector, gaining 10.01% over the past week compared to the Sensex's 2.30% increase.<BR><BR>Despite some negative indicators, such as a decrease in delivery volume and a high debt-to-EBITDA ratio, the overall sentiment appears to be buoyed by the company's strong recent performance and attractive valuation metrics, including a high return on capital employed (ROCE) of 16.05%. The stock's ability to trade at a discount compared to its peers' average historical valuations also contributes to its rising price.